[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 13 sources · 3 days · First seen · Last updated

Guselkumab reimbursement approval in Italy

Overview

Italy has approved reimbursement for the Johnson & Johnson drug guselkumab (Tremfya) to treat two specific inflammatory bowel diseases: moderate to severe active ulcerative colitis and moderate to severe active Crohn’s disease.

Guselkumab is an IL-23 selective inhibitor that can be administered via intravenous use during induction phases and subcutaneous use for maintenance. Medical experts have noted the drug’s efficacy and safety in registry studies. The approval addresses a significant health need in Italy, where an estimated 250,000 people live with inflammatory bowel diseases, a condition representing approximately one percent of the population.

Entities

Johnson & Johnson · Italy · Ulcerative colitis · Guselkumab · Guselkumab

Timeline

  1. [HEALTH] 2 sources
    Italy approves reimbursement for Guselkumab for bowel diseases

    Italy has approved reimbursement for Guselkumab, a Johnson & Johnson drug used to treat Crohn's disease and ulcerative colitis.

  2. [HEALTH] 11 sources
    Guselkumab approved for reimbursement in Italy for Crohn's and colitis

    Johnson & Johnson's guselkumab (Tremfya) has been approved for reimbursement in Italy to treat moderate to severe ulcerative colitis and Crohn's disease in adults.

Sources

cinquecolonne.it · entilocali-online.it · farmaciavirtuale.it · it-boltwise.de · lamilano.it · lecodellitorale.it · liberoquotidiano.it · notiziedi.it · quotidiano.net · quotidianodelsud.it · quotidianodifoggia.it · redazionenews.it · trapanisi.it